Microbiome and Sarcopenia in Patients With Liver Cirrhosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03080129|
Recruitment Status : Recruiting
First Posted : March 15, 2017
Last Update Posted : March 18, 2019
Protein-energy malnutrition (PEM) occurs in 65-90% of patients with liver cirrhosis. Severity of malnutrition correlates with progression of liver disease and leads to sarcopenia in 30-70% of cirrhotic patients. Malnutrition and sarcopenia are associated with an increased risk of complications and mortality.
In cirrhosis the gut microbiome is altered leading to increased gut permeability, bacterial translocation and inflammation. Since the microbiome is involved in nutrient uptake and metabolism, it is hypothesized that microbiome alterations contribute to sarcopenia. A prospective controlled cohort study to investigate the interrelation of microbiome changes and sarcopenia in cirrhosis will be conducted. Furthermore the effect of nutritional interventions on the microbiome in cirrhosis will be studied. From this study information on how the gut microbiome composition and sarcopenia are associated in cirrhosis and if modulation of the gut microbiome by nutritional interventions is feasible will be collected.
|Condition or disease||Intervention/treatment||Phase|
|Sarcopenia Liver Cirrhosis||Dietary Supplement: Fresubin energy||Not Applicable|
Protein-energy malnutrition (PEM) occurs in 65-90% of patients with chronic liver disease. PEM is caused by various factors including poor dietary intake, loss of appetite, decreased hepatic protein synthesis, malabsorption and hypermetabolism. It is associated with an increased risk of complications including ascites, hepatic encephalopathy, variceal bleeding, hepatorenal syndrome and mortality. There is a direct relation between the progression of the liver disease and the severity of malnutrition.
Malnutrition and sarcopenia in liver cirrhosis patients
PEM leads to sarcopenia as a common, but frequently overlooked, complication. Sarcopenia is defined as a decrease in muscle mass two standard deviations below the healthy young adult mean. Sarcopenia is associated with aging, chronic diseases and malignancy. To determine the severity of muscle wasting, computed tomography scan (CT) or magnetic resonance imaging (MRI) are an objective and reproducible technique. Sarcopenia negatively impacts on survival, correlates with the risk of infections, increases surgical risk and leads to a poor quality of life. Besides PEM also inflammation is of importance in the development of sarcopenia.
Diversity in the microbiome in patients with liver cirrhosis and association with sarcopenia.
The gut microbiome of liver cirrhosis patients is altered compared to healthy individuals. Dysbiosis leads to an increased gut permeability, bacterial translocation and inflammation. This contributes to fibrogenesis and may also be related to hepatocarcinogenesis. Hence, new treatment approaches in cirrhosis focus on changing the microbial landscape.
Modulation the gut microbiome may also be a strategy to reverse sarcopenia by reducing systematic inflammation.
Hypothesis and aims
There is an association between gut microbiome composition, gut permeability and the existence of sarcopenia in cirrhotic patients.
Primary hypothesis: Diversity of the gut microbiome is reduced in liver cirrhosis patients with sarcopenia compared to those without sarcopenia or healthy controls.
Secondary hypotheses: There is an association between gut microbiome composition, biomarker of gut permeability and bacterial translocation with the presence of sarcopenia in cirrhosis. Oral nutrition supplements (ONS) can influence the composition of the gut microbiome, gut permeability, bacterial translocation and inflammation.
Aims: to investigate:
- the composition of the gut microbiome
- biomarkers of gut permeability, bacterial translocation and inflammation
- the incidence and severity of sarcopenia
- the impact of oral nutrition supplements (ONS) on the gut microbiome
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||120 participants|
|Intervention Model:||Parallel Assignment|
|Primary Purpose:||Basic Science|
|Official Title:||Microbiome and Sarcopenia in Patients With Liver Cirrhosis: A Prospective Controlled Cohort Study|
|Actual Study Start Date :||April 11, 2017|
|Estimated Primary Completion Date :||July 2019|
|Estimated Study Completion Date :||December 2019|
Experimental: Cirrhosis + sarcopenia
Patients with cirrhosis will receive 200ml of an oral nutritional supplement daily for 7 days.
Dietary Supplement: Fresubin energy
dietary protein energy supplement
No Intervention: Control
Patients with sarcopenia and no evidence of cirrhosis and healthy controls
- Alpha diversity [ Time Frame: day 1 ]16s rDNA sequencing of the stool microbiome
- Zonulin [ Time Frame: day 1 ]ELISA
- diamino-oxidase [ Time Frame: day 1, day 7 ]ELISA
- Calprotectin [ Time Frame: day 1 ]ELISA
- Gut permeability [ Time Frame: change between day 1 and day 7 ]marker panel
- taxonomic composition of the microbiome [ Time Frame: day 1 ]16s rDNA sequencing of the stool microbiome
- taxonomic composition of the microbiome [ Time Frame: change between day 1 and day 7 ]16s rDNA sequencing of the stool microbiome
- lipopolysaccharide [ Time Frame: day 1 ]HEK blue cell assay
- sCD14 [ Time Frame: day 1 ]ELISA
- lipopolysaccharide binding protein [ Time Frame: day 1 ]ELISA
- bacterial DNA [ Time Frame: day 1 ]HEK blue cell assay
- bacterial translocation [ Time Frame: change between day 1 and day 7 ]marker panel
- cytokine panel [ Time Frame: day 1 ]Bead array
- carboxylated proteins [ Time Frame: day 1 ]ELISA
- advanced oxidation end products [ Time Frame: day 1 ]ELISA
- inflammation [ Time Frame: change between day 1 and day 7 ]marker panel
- myostatin [ Time Frame: day 1 ]ELISA
- fibroblast growth factor 21 [ Time Frame: day 1 ]ELISA
- insulin like growth factor 1 [ Time Frame: day 1 ]ELISA
- Irisin [ Time Frame: day 1 ]ELISA
- nutritional status [ Time Frame: day 1 ]Questionnaire
- Sarcopenia [ Time Frame: day 1 ]MR/CT scan
- face portrait [ Time Frame: day 1 ]face portraits "selfies" will be obtained and AI algorithms will be used to diagnose sarcopenia from selfies
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03080129
|Contact: Vanessa Stadlbauer-Köllner, AssocProf Dremail@example.com|
|Contact: Julia Haberl, BScfirstname.lastname@example.org|
|Medical University Graz||Recruiting|
|Contact: Vanessa Stadlbauer-Köllner, MD 0043 316 385 ext 82282 email@example.com|